OVID vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OVID Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical, Options & Structure while CVM counters with relative strength in Growth & Margin. Fundamentally, OVID trades at 1.8x Forward P/E with -4693.7% operating margin (-88.3% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, OVID sits in CONSOLIDATION (34th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OVID Revenue | CVM Revenue | OVID Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2020 | $10M | N/A | -645.4% | N/A | OVID |
| FY2021 | $210M | N/A | 59.6% | N/A | OVID |
| FY2022 | $0M | N/A | -3696.4% | N/A | OVID |
| FY2023 | $0M | N/A | -15122.7% | N/A | OVID |
| FY2024 | $0M | N/A | -10933.7% | N/A | OVID |
| FY2025 | $10M | N/A | -585.2% | N/A | OVID |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OVID | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $462.6M | $20.9M | Larger Scale | OVID |
| Trailing P/E Ratio Valuation | 1.8x | 23.0x | Lower Multiple | OVID |
| Forward P/E Ratio Valuation | 1.8x | 23.0x | Lower Multiple | OVID |
| Revenue Growth (YoY) Growth | -88.3% | -62.7% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | -4693.7% | 0.0% | Higher Margin | CVM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -35.4% | -252.5% | Higher ROE | OVID |
| 52-Week Range Position Momentum | 72% ($1โ$3) | 10% ($1โ$8) | Stronger Trend | OVID |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 97% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | OVID |
| Unified Institutional Score Composite Signal | 44.9 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | CVM |